(Quartz) – Novo Nordisk told investors that an early-stage drug trial found that an oral version of the drug amycretin leads to users losing 13% of their body weight after 12 weeks of treatment. Novo Nordisk stock was up more than 8% to a record high in Monday morning trading, at about $135 per share. (Read More)